NCT07601607 Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL Status NOT_YET_RECRUITING Phase PHASE2
NCT07583810 Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07578077 Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07562022 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma Status NOT_YET_RECRUITING Phase PHASE3
NCT07520006 Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07493148 Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL Status RECRUITING Phase PHASE2
NCT07477366 Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07451847 Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Status NOT_YET_RECRUITING Phase PHASE4
NCT07448324 Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL Status RECRUITING Phase PHASE2
NCT07444710 Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Status NOT_YET_RECRUITING Phase PHASE1
NCT07397832 CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL Status RECRUITING Phase PHASE2
NCT07365306 Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Status RECRUITING Phase PHASE2
NCT07362238 Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) Status RECRUITING Phase PHASE2
NCT07335562 A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis Status RECRUITING Phase PHASE3
NCT07297563 Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Status RECRUITING Phase PHASE2
NCT07294677 CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL Status RECRUITING Phase PHASE1/PHASE2
NCT07270835 Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma Status RECRUITING Phase PHASE4
NCT07257055 Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study Status RECRUITING Phase PHASE2
NCT07255963 Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL Status RECRUITING Phase PHASE2